Among @ SHARP participants who had functioning vascular access at randomization , allocation to simvastatin plus ezetimibe resulted in a @ % proportional reduction in vascular access occlusive events ( @ -LSB- @ % -RSB- for simvastatin/ezetimibe versus @ -LSB- @ % -RSB- for placebo ; risk ratio -LSB- RR -RSB- , @ ; @ % confidence interval -LSB- @ % CI -RSB- , @ to @ ; P = @ ) .